By evaluating the clinical significance of DNA2 in patients with ovarian cancer, the cancer type with the most prevalent somatic TP53 mutations, we found that high expression of DNA2 is associated with more advanced diseases, poor prognosis and acquired resistance to clinical response (Fig. 1F; Supplementary Fig. S2A–S2E). This evidence concerns the gene DNA2 and ovarian carcinoma.